Prolonged QTc Interval Clinical Trial
Official title:
A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50 mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment.
Post-marketing study to evaluate the effect of deferiprone and deferiprone 3-O-glucuronide on QTc prolongation in healthy volunteers after administration of a single therapeutic (33 mg/kg) and supratherapeutic (50 mg/kg) oral dose of deferiprone and moxifloxacin (Avelox®). ;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03916341 -
Smoking and Ventricular Repolarization
|
N/A | |
| Completed |
NCT04819906 -
Effect of Estetrol Monohydrate (E4) on QTc Interval
|
Phase 1 | |
| Completed |
NCT01352130 -
Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc
|
Phase 4 | |
| Completed |
NCT03951402 -
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT03958123 -
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03278522 -
Ramosetron Pre-treatment for PONV and QT Prolongation
|
Phase 4 | |
| Completed |
NCT01590979 -
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation
|
N/A |